文献速递心脑血管急症重症综合管理与镇静镇痛

沙库巴曲/缬沙坦对比标准药物治疗对射血分数保留的心力衰竭患者血浆NT-proBNP浓度和次极量运动能力的影响:PARALLAX随机临床试验

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在LVEF>40%的心力衰竭患者中,沙库巴曲/缬沙坦较标准肾素-血管紧张素系统抑制剂或安慰剂显著降低12周NT-proBNP,但未显著改善24周6分钟步行距离。

PARALLAX试验在32个国家396个中心纳入2572例LVEF>40%、NT-proBNP升高、有结构性心脏病且生活质量下降的慢性心力衰竭患者,随机接受沙库巴曲/缬沙坦(n=1286)或基于背景药物的个体化对照(依那普利、缬沙坦或安慰剂,n=1286)。主要终点为12周NT-proBNP较基线变化和24周6分钟步行距离较基线变化。结果显示沙库巴曲/缬沙坦组12周NT-proBNP降低幅度显著大于对照组(调整几何均值比0.84,95%CI 0.80-0.88,P<.001),但24周6分钟步行距离组间差异无统计学意义(增加9.7 m vs 12.2 m,调整均值差-2.5 m,95%CI -8.5至3.5,P=.42)。生活质量评分和NYHA心功能分级改善组间亦无显著差异。

要点

  • 在LVEF>40%的心力衰竭患者中,沙库巴曲/缬沙坦组12周NT-proBNP较基线调整几何均值比为0.82 pg/mL,对照组为0.98 pg/mL,组间调整几何均值比0.84(95%CI 0.80-0.88;P<.001)。
  • 24周6分钟步行距离较基线增加沙库巴曲/缬沙坦组9.7 m vs 对照组12.2 m,调整均值差-2.5 m(95%CI -8.5至3.5;P=.42),无统计学显著差异。
  • 堪萨斯城心肌病问卷临床总结评分变化沙库巴曲/缬沙坦组12.3 vs 对照组11.8,均值差0.52(95%CI -0.93至1.97),无显著差异;NYHA分级改善率23.6% vs 24.0%(调整OR 0.98;95%CI 0.81-1.18)。
  • 沙库巴曲/缬沙坦组最常见不良事件为低血压(14.1% vs 5.5%)、白蛋白尿(12.3% vs 7.6%)和高钾血症(11.6% vs 10.9%)。
  • 作者结论认为,沙库巴曲/缬沙坦较标准RAS抑制剂或安慰剂显著降低12周NT-proBNP,但未显著改善24周6分钟步行距离;需进一步研究评估其潜在临床获益。

适用人群与场景

  • 慢性心力衰竭、左心室射血分数(LVEF)>40%、NT-proBNP水平升高、结构性心脏病且生活质量下降的患者。
  • 共2572例随机患者,平均年龄72.6岁(SD 8.5岁),女性1301例(50.7%)。
  • 纳入标准:LVEF>40%,NT-proBNP升高,结构性心脏病,生活质量下降。

诊断标准与关键阈值

  • LVEF>40%。
  • NT-proBNP水平升高(基线中位数:沙库巴曲/缬沙坦组786 pg/mL,对照组760 pg/mL)。
  • 结构性心脏病。
  • 生活质量下降。

处置流程与药物剂量

  • 沙库巴曲/缬沙坦组:沙库巴曲/缬沙坦(n=1286),具体剂量、给药途径及频次原文未报告。
  • 对照组:基于背景药物的个体化对照(n=1286),即依那普利、缬沙坦或安慰剂,按既往肾素-血管紧张素系统抑制剂使用情况分层。
  • 治疗疗程:24周。

红旗征与不能漏的情况

  • 低血压(沙库巴曲/缬沙坦组14.1% vs 对照组5.5%)。
  • 白蛋白尿(沙库巴曲/缬沙坦组12.3% vs 对照组7.6%)。
  • 高钾血症(沙库巴曲/缬沙坦组11.6% vs 对照组10.9%)。

研究设计与关键结果

  • 研究类型:24周随机、双盲、平行组临床试验(2017年8月至2019年10月),在32个国家396个中心进行;筛查4632例,随机2572例,2240例(87.1%)完成试验。
  • 主要终点1:12周血浆NT-proBNP较基线变化,沙库巴曲/缬沙坦组调整几何均值比0.82 pg/mL vs 对照组0.98 pg/mL,组间调整几何均值比0.84(95%CI 0.80-0.88;P<.001)。
  • 主要终点2:24周6分钟步行距离较基线变化,沙库巴曲/缬沙坦组增加9.7 m vs 对照组增加12.2 m,调整均值差-2.5 m(95%CI -8.5至3.5;P=.42)。
  • 次要终点:24周堪萨斯城心肌病问卷临床总结评分变化,沙库巴曲/缬沙坦组12.3 vs 对照组11.8,均值差0.52(95%CI -0.93至1.97)。
  • 次要终点:24周NYHA心功能分级改善率,沙库巴曲/缬沙坦组23.6% vs 对照组24.0%,调整OR 0.98(95%CI 0.81-1.18)。
  • 不良事件:沙库巴曲/缬沙坦组 vs 对照组最常见不良事件为低血压(14.1% vs 5.5%)、白蛋白尿(12.3% vs 7.6%)、高钾血症(11.6% vs 10.9%)。

证据类型、等级与局限

  • 证据类型:随机、双盲、平行组临床试验(RCT)。
  • 局限:原文结论指出需进一步研究评估沙库巴曲/缬沙坦在这些患者中的潜在临床获益(Further research is warranted)。

对床旁实践的改变

  • 在LVEF>40%的心力衰竭患者中,沙库巴曲/缬沙坦较标准RAS抑制剂或安慰剂显著降低12周NT-proBNP,但未显著改善24周6分钟步行距离、生活质量评分或NYHA分级。
  • 沙库巴曲/缬沙坦组低血压(14.1% vs 5.5%)、白蛋白尿(12.3% vs 7.6%)和高钾血症(11.6% vs 10.9%)发生率高于对照组。
  • 作者认为,需进一步研究评估沙库巴曲/缬沙坦在这些患者中的潜在临床获益。

指南或共识出处

  • PARALLAX随机临床试验(ClinicalTrials.gov注册号NCT03066804),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: There is limited evidence on the benefits of sacubitril/valsartan vs broader renin angiotensin system inhibitor background therapy on surrogate outcome markers, 6-minute walk distance, and quality of life in patients with heart failure and mildly reduced or preserved left ventricular ejection fraction (LVEF >40%).

OBJECTIVE: To evaluate the effect of sacubitril/valsartan on N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, 6-minute walk distance, and quality of life vs background medication-based individualized comparators in patients with chronic heart failure and LVEF of more than 40%.

DESIGN, SETTING, AND PARTICIPANTS: A 24-week, randomized, double-blind, parallel group clinical trial (August 2017-October 2019). Of 4632 patients screened at 396 centers in 32 countries, 2572 patients with heart failure, LVEF of more than 40%, elevated NT-proBNP levels, structural heart disease, and reduced quality of life were enrolled (last follow-up, October 28, 2019).

INTERVENTIONS: Patients were randomized 1:1 either to sacubitril/valsartan (n = 1286) or to background medication-based individualized comparator (n = 1286), ie, enalapril, valsartan, or placebo stratified by prior use of a renin angiotensin system inhibitor.

MAIN OUTCOMES AND MEASURES: Primary end points were change from baseline in plasma NT-proBNP level at week 12 and in the 6-minute walk distance at week 24. Secondary end points were change from baseline in quality of life measures and New York Heart Association (NYHA) class at 24 weeks.

RESULTS: Among 2572 randomized patients (mean age, 72.6 years [SD, 8.5 years]; 1301 women [50.7%]), 2240 (87.1%) completed the trial. At baseline, the median NT-proBNP levels were 786 pg/mL in the sacubitril/valsartan group and 760 pg/mL in the comparator group. After 12 weeks, patients in the sacubitril/valsartan group (adjusted geometric mean ratio to baseline, 0.82 pg/mL) had a significantly greater reduction in NT-proBNP levels than did those in the comparator group (adjusted geometric mean ratio to baseline, 0.98 pg/mL) with an adjusted geometric mean ratio of 0.84 (95% CI, 0.80 to 0.88; P < .001). At week 24, there was no significant between-group difference in median change from baseline in the 6-minute walk distance with an increase of 9.7 m vs 12.2 m (adjusted mean difference, -2.5 m; 95% CI, -8.5 to 3.5; P = .42). There was no significant between-group difference in the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (12.3 vs 11.8; mean difference, 0.52; 95% CI, -0.93 to 1.97) or improvement in NYHA class (23.6% vs 24.0% of patients; adjusted odds ratio, 0.98; 95% CI, 0.81 to 1.18). The most frequent adverse events in the sacubitril/valsartan group vs the comparator group were hypotension (14.1% vs 5.5%), albuminuria (12.3% vs 7.6%), and hyperkalemia (11.6% vs 10.9%).

CONCLUSIONS AND RELEVANCE: Among patients with heart failure and left ventricular ejection factor of higher than 40%, sacubitril/valsartan treatment compared with standard renin angiotensin system inhibitor treatment or placebo resulted in a significantly greater decrease in plasma N-terminal pro-brain natriuretic peptide levels at 12 weeks but did not significantly improve 6-minute walk distance at 24 weeks. Further research is warranted to evaluate potential clinical benefits of sacubitril/valsartan in these patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03066804.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021. PMID: 34783839. doi:10.1001/jama.2021.18463

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。